Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionImpaired clearance of methotrexate in organic anion transporter 3 (Slc22a8) knockout mice: a gender specific impact of reduced folatesThe role of drug transporters in the kidney: lessons from tenofovirDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryAssociation study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patientsNDUFA2 complex I mutation leads to Leigh diseaseR-flurbiprofen attenuates experimental autoimmune encephalomyelitis in miceDeregulated hepatic metabolism exacerbates impaired testosterone production in Mrp4-deficient mice.Glutathione status and the renal elimination of inorganic mercury in the Mrp2(-/-) mouse.Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations.Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity.Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4.Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation.Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia.PharmGKB summary: methotrexate pathway.Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity.PharmGKB summary: ibuprofen pathways.Toxicological significance of renal Bcrp: Another potential transporter in the elimination of mercuric ions from proximal tubular cellsN-lactoyl-amino acids are ubiquitous metabolites that originate from CNDP2-mediated reverse proteolysis of lactate and amino acids.Mechanisms of Thymoquinone Hepatorenal Protection in Methotrexate-Induced Toxicity in RatsIbuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infectionContribution of tumoral and host solute carriers to clinical drug response.Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones.ATP-binding Cassette Subfamily C Member 5 (ABCC5) Functions as an Efflux Transporter of Glutamate Conjugates and Analogs.Chalcogenopyrylium dyes as differential modulators of organic anion transport by multidrug resistance protein 1 (MRP1), MRP2, and MRP4Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics.Localization of multidrug resistance-associated protein 2 in the nonpigmented ciliary epithelium of the eye.Pharmacogenetics of analgesics: toward the individualization of prescription.Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response.Pharmacokinetic drug-drug interactions with methotrexate in oncology.Interactions between oral antineoplastic agents and concomitant medication: a systematic review.Renal transport of organic anions and cations.Practical issues with high dose methotrexate therapy.RETRACTED: Reanalysis of the gene expression profile in chronic pancreatitis via bioinformatics methods.
P2860
Q24273350-4047F90A-0705-4693-A9E6-76072E7D48B7Q24649482-B634E820-47BD-47B9-ABA4-EFC706D2D0A5Q26866489-2D7D8FED-2D31-45D2-B5C6-24ACC0F4A5F1Q28081272-3BE5F66F-223D-4540-A7A4-07636B93AAA0Q28255901-C51D7E87-0AFB-411D-A981-3D9538CB1E60Q28282142-05A8A23E-B21B-49DC-ACF7-BF803E94233EQ28651801-C99FF2CF-C061-4358-A06E-2AB4029A0AD2Q30419764-D4FC07EE-CB73-42AF-84FE-FEFED1557363Q31139351-3235188C-5357-4A16-A46B-BCD87FDF18FEQ33714593-1ECD20F0-E4DD-4CC1-BF18-6FA4DC6DC696Q33764995-7C25096D-9542-4F60-9F51-DEC689D4390EQ33869303-45BDFCAC-EF57-4D07-8569-B5AEF9C37F1AQ33874609-C44C800E-ADA6-4919-8B54-3D74E40B12EBQ34035243-7533E499-4647-480C-8FA0-0071632BAF20Q34065294-36B44078-3FA4-4022-8BAD-DB6C2404539DQ34233691-F67FFA5A-5B8C-49EB-8F0C-194DA469EEBEQ34596040-33BC5CE8-5F30-4E43-95C4-C424E699DF16Q34606100-3F34F81E-A880-4FE4-B061-EB968509D16CQ34619344-A2DAF877-E491-46BD-886E-6B0A76FD2E41Q35115680-39042173-C490-4DC2-B6DC-A1EA63EA0C9DQ35155913-9918BDF2-7594-4F0F-98DA-3FCA024E1FEDQ35164718-DCABF229-EBEB-4819-9A46-FB1F471338C5Q35602719-8A3369C8-91A1-4BD3-BC68-05A5F34410C7Q35669404-902F7194-4E71-48EA-8964-28F75BC0C08DQ35683026-823A4F56-B350-4B15-8F63-F75FF3D9AF2AQ35746053-651C1831-8CF7-4BB5-B146-25A4EC634AC0Q35946876-A9F52458-1372-4ACB-B611-8E684F10E5DBQ36150190-C4B424DA-7FFF-443B-8537-AC4B4C3DADBBQ36381928-A50C321E-AC10-40A2-ACC7-C457ED2F71C9Q36852514-DC4A8F61-ADA0-428F-BCC8-6B3A59E48310Q37076348-D92055E7-5120-4A12-B245-1705D94AABCEQ37148784-A0064279-3556-4C0A-97EA-FC43A422674DQ37168510-DE50106E-101C-47A3-8103-58DDCF3F072BQ37205954-9EAC63BA-F227-4F60-91A1-69B73CDE9E47Q37428056-F88E9856-C7BD-4719-B3C7-7A2421C58D04Q37960131-F3144E37-789C-4505-B7CC-76334547C9CDQ38099040-72B6E38E-DE7A-475E-9DE6-DBD0A235B4A5Q38111725-1DC2F4F6-F744-4172-969D-0D6BF88A6344Q38243780-FAFC0ED3-12B8-4DC5-9DEE-2215D0E905D3Q38429154-CB10F9A6-62A9-487A-AF97-7D91EB2DE9DA
P2860
Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Interaction of nonsteroidal an ...... diated methotrexate transport.
@en
type
label
Interaction of nonsteroidal an ...... diated methotrexate transport.
@en
prefLabel
Interaction of nonsteroidal an ...... diated methotrexate transport.
@en
P2093
P356
P1476
Interaction of nonsteroidal an ...... diated methotrexate transport.
@en
P2093
Azza A K El-Sheikh
Frans G M Russel
Jan B Koenderink
Jeroen J M W van den Heuvel
P304
P356
10.1124/JPET.106.110379
P407
P577
2006-09-27T00:00:00Z